As of 2025-07-12, the EV/EBITDA ratio of Talis Biomedical Corp (TLIS) is 0.37. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TLIS's latest enterprise value is -15.51 mil USD. TLIS's TTM EBITDA according to its financial statements is -41.45 mil USD. Dividing these 2 quantities gives us the above TLIS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 16.0x - 19.0x | 17.9x |
| Forward P/E multiples | 19.8x - 23.3x | 22.2x |
| Fair Price | (59.74) - 6.43 | (30.47) |
| Upside | -1463.9% - 46.9% | -795.7% |
| Date | EV/EBITDA |
| 2025-07-08 | 1.09 |
| 2025-06-27 | 1.10 |
| 2025-06-24 | 1.09 |
| 2025-06-18 | 1.02 |
| 2025-06-12 | 1.10 |
| 2025-06-10 | 1.10 |
| 2025-06-04 | 1.10 |
| 2025-06-03 | 1.09 |
| 2025-05-29 | 1.08 |
| 2025-05-23 | 1.08 |
| 2025-05-15 | 1.10 |
| 2025-05-14 | 1.10 |
| 2025-05-12 | 1.10 |
| 2025-05-02 | 1.05 |
| 2025-04-30 | 1.05 |
| 2025-04-29 | 1.05 |
| 2025-04-28 | 1.05 |
| 2025-04-25 | 1.05 |
| 2025-04-24 | 1.05 |
| 2025-04-23 | 1.05 |
| 2025-04-21 | 1.05 |
| 2025-04-17 | 1.03 |
| 2025-04-14 | 1.03 |